作者
Pierluigi Reveglia, Carmela Paolillo, Gabriella Ferretti, Armando De Carlo, Antonella Angiolillo, Rosarita Nasso, Mafalda Caputo, Carmela Matrone, Alfonso Di Costanzo, Gaetano Corso
发表日期
2021/9
来源
Metabolomics
卷号
17
期号
9
页码范围
78
出版商
Springer US
简介
Background
Alzheimer's disease (AD) is one of the most common causes of dementia in old people. Neuronal deficits such as loss of memory, language and problem-solving are severely compromised in affected patients. The molecular features of AD are Aβ deposits in plaques or in oligomeric structures and neurofibrillary tau tangles in brain. However, the challenge is that Aβ is only one piece of the puzzle, and recent findings continue to support the hypothesis that their presence is not sufficient to predict decline along the AD outcome. In this regard, metabolomic-based techniques are acquiring a growing interest for either the early diagnosis of diseases or the therapy monitoring. Mass spectrometry is one the most common analytical platforms used for detection, quantification, and characterization of metabolic biomarkers. In the past years, both targeted and untargeted strategies have been applied to identify …
学术搜索中的文章
P Reveglia, C Paolillo, G Ferretti, A De Carlo… - Metabolomics, 2021